HIT Consultant January 10, 2025
Christopher McSpiritt, Head of life sciences at Domino Data Lab

Data science teams in the life sciences industry are experiencing a significant change that will transform how clinical data is analyzed, opening the door to new possibilities for innovation. The transition isn’t happening overnight, but such incremental approaches are necessary to ensure success in such a highly regulated environment.

For decades, SAS was “it” in life sciences. If you wanted to be a data scientist in the industry, you had to know SAS. However, recently there has been a move toward open-source tools among organizations under growing pressure to cut costs and innovate faster. But open source comes with its own set of challenges—especially for such a tightly regulated industry. For the transition to work, teams must strike a careful...

Today's Sponsors

Venturous
Got healthcare questions? Just ask Transcarent

Today's Sponsor

Venturous

 
Topics: Biotechnology, Pharma / Biotech
How Pharmacy Deserts, Biosimilars, and Market Trends Are Shaping Managed Care
CVS Caremark taps Omada on GLP-1 program
InnovationRx: Trump Administration Health Agency Layoffs Threaten Biotech Innovation
Which Biopharma Startups Made the Cut for INVEST Pitch Perfect?
PBMs push private-label biosimilars in 2025 formularies

Share This Article